Quick Answer
Core Scientific, Inc./tx reported Cash and Equivalents of $311.38 million for fiscal year 2025.
Core Scientific, Inc./tx Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $311.38M | -62.8% |
| 2024 | $836.20M | +1558.8% |
| 2023 | $50.41M | +217.4% |
| 2022 | $15.88M | -86.5% |
| 2021 | $117.87M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $453.44M | +79.2% | -22.0% |
| June 30, 2025 | $581.35M | +504.8% | -16.7% |
| March 31, 2025 | $697.94M | +611.3% | -16.5% |
| December 31, 2024 | $836.20M | +1558.8% | +230.5% |
| September 30, 2024 | $253.02M | +500.3% | +163.2% |
| June 30, 2024 | $96.12M | +66.9% | -2.0% |
| March 31, 2024 | $98.12M | +106.6% | +94.7% |
| December 31, 2023 | $50.41M | +217.4% | +19.6% |
- Core Scientific, Inc./tx showed a decrease of -62.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, Core Scientific, Inc./tx’s cash and equivalents has grown by 164.2% (from $117.87 million to $311.38 million).
- The most recent figure is from Core Scientific, Inc./tx’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: